Visceral leishmaniasis, caused by Leishmania infantum in New World countries, is the most serious and potentially fatal form of leishmaniasis, if left untreated. There are currently no effective prophylactic measures, and therapeutic options are limited. Therefore, we investigated whether the aromatase inhibitor letrozole (LET), which is already used to treat breast cancer, has an antileishmanial activity and/or immunomodulatory potential and therefore may be used to treat L. infantum infection. LET was active against L. infantum promastigote and amastigote life cycle stages in an i n vitro infection model using human THP-1 cell-derived macrophages. In human peripheral blood leukocytes ex vivo , LET reduced the internalized forms of L. infantum by classical monocytes and activated neutrophils. Concomitantly, LET stimulated the production of IL-12/TNF-α and decreased the production of IL-10/TGF-β by peripheral blood phagocytes, while in T and B cells, it promoted the production of TNF-α/IFN-γ and decreased that of IL-10. In a murine infection model, LET significantly reduced the parasite load in the liver after just 5 days and in the spleen after 15 days. During in vivo treatment with LET, the production of TNF-α/IFN-γ also increased. In addition, the proportion of developing granulomas decreased and that of mature granulomas increased in the liver, while there was no significant change in organ architecture in the spleen. Based on these data, repositioning of LET may be promising for the treatment of visceral leishmaniasis in humans.
5 August 2026 in Antimicrobial Agents and Chemotherapy
Leishmania infantum depends on tightly regulated signaling pathways to sustain growth, stress adaptation, and infectivity. Glycogen synthase kinase 3 (GSK-3) is a conserved serine/threonine kinase involved in multiple cellular processes; however, its functional role in Leishmania remains poorly defined. Here, we investigated the role of the short isoform of GSK-3 (GSK-3s) in L. infantum using a CRISPR/Cas9-based genetic approach. Attempts to generate chromosomal GSK-3s null mutants were unsuccessful, suggesting that GSK-3s is essential for parasite viability. Chromosomal gene deletion was achieved only after episomal complementation with L. braziliensis GSK-3s, generating a GSK3s-deficient knockdown L. infantum line ( LiΔchrGSK3::LbGSK3 ). Quantitative PCR revealed a 3.8-fold and 9.6-fold reduction in GSK-3s transcript levels in this L. infantum line compared with Li::Cas9 and GSK3-overexpressing ( Li::LbGSK3 ) parasites, respectively. Reduced GSK-3s expression in this parasite line resulted in severe growth impairment, morphological alterations, and cell-cycle dysregulation. GSK-3s knockdown promastigotes exhibited a 5.3-fold increase in resistance to trivalent antimony and a 1.77-fold increase in resistance to miltefosine, as well as a striking 111-fold increase in resistance to the GSK-3 inhibitor 6-bromo-5-methylindirubin-3′-oxime (6-BIO), supporting the specificity of this compound toward parasite GSK-3s. In addition, GSK-3s-deficient parasites displayed a 7.5-fold increase in tolerance to hydrogen peroxide-induced oxidative stress, accompanied by differential modulation of antioxidant defense gene transcripts. In infection models, GSK-3s knockdown parasites displayed reduced early infectivity in THP-1-derived macrophages and significantly lower splenic parasite burdens, with reductions of 1.5-fold in BALB/c mice and 2.5-fold in IFN- γ⁻/⁻ C57BL/6 mice. Collectively, these findings suggest that GSK-3s may play an important role in regulating L. infantum growth, stress adaptation, drug response, and infectivity, indicating its potential as a target for anti-leishmanial drug development.